Pro Medicus Ltd (ASX: PME) Share Price and News

Price

Movement

( )

(20 mins delayed)

52 Week Range

-

 
1 Year Return

 

Pro Medicus Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $23.36 billion
P/E Ratio 238.03
Dividend Yield 0.21%
Shares Outstanding 104.48 million
Earnings per share 0.939
Dividend per share 0.50
Year To Date Return -10.51%
Earnings Yield 0.42%
Franking 100%
Share Price

Day Change

( )

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

  • Should you invest $1,000 in Pro Medicus right now?

    Before you buy Pro Medicus shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Pro Medicus wasn't one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys...

    See The 5 Stocks *Returns as of 6 March 2025

  • Pro Medicus Ltd (ASX: PME)
    Latest News

    Doctor doing a telemedicine using laptop at a medical clinic
    Healthcare Shares

    Up 129% in a year, here are 3 reasons to buy Pro Medicus shares today

    A leading expert recommends buying the dip on Pro Medicus shares.

    Read more »

    Two brokers analysing stocks.
    Share Market News

    5 things to watch on the ASX 200 on Friday

    Will the market end the week on a high? Let's find out.

    Read more »

    Man holding out Australian dollar notes, symbolising dividends.
    Growth Shares

    Top ASX stocks to buy right now with $7,000

    Analysts think these shares would be top picks for your money.

    Read more »

    Cropped shot of an attractive young female scientist working on her computer in the laboratory.
    Healthcare Shares

    Pro Medicus shares are down 20%. Is this a buying opportunity?

    One of the ASX’s best companies is now materially cheaper.

    Read more »

    Ecstatic woman looking at her phone outside with her fist pumped.
    Growth Shares

    3 excellent ASX 200 growth shares to buy and hold with $3,000

    Here's why analysts think these shares could be top picks for growth investors.

    Read more »

    Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
    Broker Notes

    These ASX 200 stocks could rise 25% to 40% after the market selloff

    Analysts believe these shares have the potential to generate big returns over the next 12 months.

    Read more »

    A couple are happy sitting on their yacht.
    How to invest

    Why I think ASX 200 shares remain the best path to long-term wealth

    Building wealth in the share market doesn't have to be difficult. Here are some simple steps to take.

    Read more »

    Cheerful boyfriend showing mobile phone to girlfriend in dining room. They are spending leisure time together at home and planning their financial future.
    Growth Shares

    The top ASX shares to buy right away with $3,000

    Here are a couple of shares that analysts think would be top picks for Aussie investors.

    Read more »

    Three people gather around a large computer screen where they are looking at something that is captivating their interest with a graphic image of data and digital technology material superimposed to the right hand third of the image.
    Technology Shares

    2 fantastic ASX 200 tech stocks to buy after the selloff

    These tech stocks have been sold off and could be quality buys according to analysts.

    Read more »

    Woman using a pen on a digital stock market chart in an office.
    Growth Shares

    10 excellent ASX shares to buy in March

    What are analysts recommending this month? Let's find out.

    Read more »

    Two lab workers fist pump each other.
    Healthcare Shares

    2 ASX healthcare shares rated as top buys

    Are these two names healthy choices for your portfolio? Let's see.

    Read more »

    Ecstatic woman looking at her phone outside with her fist pumped.
    Growth Shares

    The ultimate ASX growth shares to buy with $2,000 in March

    Analysts think these shares could be among the best of the best for growth investors.

    Read more »

    Frequently Asked Questions

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    27 Feb 2025 $0.2500 100.00% Interim 21 Mar 2025
    04 Sep 2024 $0.2200 100.00% Final 26 Sep 2024
    29 Feb 2024 $0.1800 100.00% Interim 22 Mar 2024
    06 Sep 2023 $0.1700 100.00% Final 28 Sep 2023
    02 Mar 2023 $0.1300 100.00% Interim 24 Mar 2023
    08 Sep 2022 $0.1200 100.00% Final 30 Sep 2022
    03 Mar 2022 $0.1000 100.00% Interim 25 Mar 2022
    09 Sep 2021 $0.0800 100.00% Final 01 Oct 2021
    04 Mar 2021 $0.0700 100.00% Interim 19 Mar 2021
    10 Sep 2020 $0.0600 100.00% Final 02 Oct 2020
    05 Mar 2020 $0.0600 100.00% Interim 20 Mar 2020
    12 Sep 2019 $0.0450 100.00% Final 04 Oct 2019
    12 Mar 2019 $0.0250 100.00% Special Cash 17 May 2019
    07 Mar 2019 $0.0350 100.00% Interim 22 Mar 2019
    06 Sep 2018 $0.0350 100.00% Final 27 Sep 2018
    08 Mar 2018 $0.0250 100.00% Interim 23 Mar 2018
    07 Sep 2017 $0.0000 100.00% Final 28 Sep 2017
    08 Sep 2016 $0.0150 0.00% Final 29 Sep 2016
    10 Mar 2016 $0.0150 0.00% Interim 24 Mar 2016
    15 Mar 2006 $0.0050 100.00% Special 05 Apr 2006
    15 Mar 2006 $0.0200 100.00% Interim 05 Apr 2006
    14 Sep 2005 $0.0050 100.00% Special Cash 04 Oct 2005
    14 Sep 2005 $0.0275 100.00% Final 04 Oct 2005
    16 Mar 2004 $0.0125 100.00% Interim 05 Apr 2004

    PME ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Pro Medicus Ltd

    Pro Medicus Ltd (ASX: PME) is a provider of medical imaging technology globally. The company is recognised as a leading supplier of radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions for medical practices and hospitals.

    Pro Medicus's RIS technology products also include medical accounting, clinical reporting, appointments/scheduling, and marketing/management applications. The company's services to the imaging sector cover workflow mapping and optimisation, network design and implementation, hardware sourcing and configuration, and staff and management training.

    Pro Medicus has offices in Australia, Germany, and the US with its products adopted by many top-tier hospitals and health facilities, particularly in the US market.

    PME Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    21 Mar 2025 $223.58 $-15.47 -6.47% 927,442 $237.90 $239.49 $223.58
    20 Mar 2025 $239.05 $6.18 2.65% 459,342 $236.08 $240.65 $234.50
    19 Mar 2025 $232.87 $-0.12 -0.05% 190,305 $230.13 $237.00 $230.13
    18 Mar 2025 $232.99 $-1.73 -0.74% 220,017 $234.76 $236.58 $229.25
    17 Mar 2025 $234.72 $0.64 0.27% 185,051 $236.60 $237.80 $232.62
    14 Mar 2025 $234.08 $2.59 1.12% 241,962 $228.99 $234.08 $228.51
    13 Mar 2025 $231.49 $3.24 1.42% 300,208 $232.20 $233.84 $228.00
    12 Mar 2025 $228.25 $-0.94 -0.41% 621,833 $224.55 $229.81 $219.28
    11 Mar 2025 $229.19 $-26.74 -10.45% 542,110 $251.00 $251.20 $226.19
    10 Mar 2025 $255.93 $1.93 0.76% 202,401 $252.10 $257.98 $252.10
    07 Mar 2025 $254.00 $-11.05 -4.17% 337,461 $264.00 $266.37 $253.30
    06 Mar 2025 $265.05 $2.65 1.01% 332,893 $261.08 $266.45 $255.90
    05 Mar 2025 $262.40 $3.05 1.18% 192,216 $258.30 $262.40 $255.00
    04 Mar 2025 $259.35 $-2.03 -0.78% 250,375 $259.95 $260.50 $251.30
    03 Mar 2025 $261.38 $8.13 3.21% 262,812 $261.91 $267.00 $256.00
    28 Feb 2025 $253.25 $-9.83 -3.74% 540,468 $256.99 $256.99 $249.44
    27 Feb 2025 $263.08 $-10.11 -3.70% 240,999 $273.23 $274.10 $260.28
    26 Feb 2025 $273.19 $-10.32 -3.64% 236,695 $275.00 $278.50 $268.50
    25 Feb 2025 $283.51 $0.20 0.07% 156,197 $283.25 $287.31 $280.39
    24 Feb 2025 $283.31 $-2.50 -0.87% 158,415 $279.84 $285.20 $277.01
    21 Feb 2025 $285.81 $-0.28 -0.10% 201,303 $284.51 $288.16 $276.22

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    12 Mar 2025 Anthony Glenning Buy 50 $10,979
    On-market trade.
    14 Feb 2025 Alice Williams Buy 125 $34,086
    On-market trade.
    04 Dec 2024 Sam Hupert Sell 1,000,000 $256,730,000
    On-market trade.
    04 Dec 2024 Anthony Hall Sell 1,000,000 $256,730,000
    On-market trade.
    30 Oct 2024 Alice Williams Sell 850 $160,879
    On-market trade.
    13 Sep 2024 Anthony Hall Transfer 35,000 $5,753,650
    Off-market transfer. Estimated value
    26 Aug 2024 Alice Williams Buy 350 $52,013
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Sam Aaron Hupert Chief Executive OfficerManaging Director Oct 2007
    Dr Hupert commenced General Practice in 1980. Realising the potential for computers in medicine he left general practice in late 1984 to devote himself full time to managing the Group. Sam served as CEO from the time he co-founded the company until October 2007 at which time he stepped down to become an executive director. Sam resumed full time CEO activities in October of 2010.
    Mr Anthony Barry Hall Executive DirectorTechnology Director Jan 1983
    Mr Hall has been principal architect and developer of the core software systems.
    Mr Peter Terence Kempen Non-Executive ChairmanNon-Executive Director Mar 2008
    Mr Kempen is Chairman of Australasian Leukemia and Lymphoma Group. He is also a Trustee of the Barr Family Foundation and a member of the Board of St Hilda's College Ltd, University of Melbourne. Peter has previously been Chairman of Patties Food Limited, Chairman of Danks Holdings Limited, Chairman of Ivanhoe Grammar School and Managing Partner of Ernst & Young Corporate Finance Australia. Peter was appointed a Member in the General Division of the Order of Australia (AM) in the 2018 Queen's Birthday Honors.
    Ms Alice Joan Morrice Williams Non-Executive Director Sep 2021
    Ms Williams is also a non-executive director of Vocus Group, Djerriwarrh Investments, Australian Submarine Corporation (ASC Pty Ltd) and Mercer Investments Australia Ltd. She is chair of the Audit & Risk Committee of Djerriwarrh Investments, ASC and Vocus Group and is a member of the Audit & Risk Committee and Due Diligence Committee of Mercer Investments (Australia) Ltd. Alice holds other board positions with Tobacco Free Portfolios and is on the Advisory Council of the Florey Institute of Neuroscience Novell Project. Previous board roles include Director and Chair of the Audit Committee of Cooper Energy, Chair of Nomination, Remuneration and Human Resources Committee and Non-Executive Director of Equity Trustees Ltd, and Non-Executive member of the Foreign Investment Review Board. Alice is Chair of Risk committee and also serves on the People & Culture committee.
    Ms Deena Robyn Shiff Non-Executive Director Aug 2020
    Ms Shiff is an Independent Member of the board of the Global Alliance for Vaccines and Immunisation, the multi-lateral global health fund based in Geneva. Deena is also on the board of Opera Australia and is the Chairman of AROSE (Australian Remote Operations in Space and Earth), and the Chairman of the International Advisory Board of the A.R.C Centre of Excellence, on Automated Decision Making and Society. Previous board roles include Chairman of the global board of BAI Communications and board member of infrastructure Australia, Chairman of the Government's Export Credit Agency EFIC, as well as board roles in a number of venture capital backed growth stage ICT companies. Deena has served as a Group Managing Director at Telstra, where she led the Wholesale Division Group, established and led Telstra Business and founded Telstra's corporate venture capital arm, Telstra Ventures. Deena has also held in house regulatory and legal positions and has been a Partner of the law firm Mallesons Stephen Jacques. Deena is Chair of the People & Culture committee and serves on the Risk committee.
    Mr Anthony James Glenning Non-Executive Director May 2016
    Mr Glenning is the fund manager of Skalata Ventures, investing in early-stage companies to help them scale and grow into significant and sustainable businesses. Anthony has previously been an Investment Director at Starfish Ventures and was the founder and CEO of Tonic Systems and a founding Non-Executive Director of Cameron Systems. He has also held software engineering positions at Google and Sun Microsystems Inc. Anthony also serves on the People & Culture committee and Risk committee.
    Dr Leigh Bernard Farrell Non-Executive Director Sep 2017
    Dr Farrell is the Managing Director of AdNED Pty Ltd, non-executive director of both Ena Respiratory Pty Ltd and Axelia Oncology Pty Ltd, a member of the Walter and Eliza Hall Institute of Medical Research Board Commercialisation Committee, a member of the Independent Advisory Council of Medicines Australia, a member of the Scientific and Industry Advisory Committee of the Australian Research Council Centre for Cryo electron Microscopy of Membrane Proteins and, Chair of the Scientific Advisory Board of Island Pharmaceuticals Ltd. Leigh was previously Head of Health Security Systems Australia, a Division of DMTC Ltd, Senior Vice President, Commercial of Certara USA, Inc. where he was responsible for Asia Pacific Commercial. Prior to this, he was Chairman and COO of d3 Medicine LLC, which was acquired by Certara USA, Inc. Prior to these appointments, Leigh was Vice President of Business Development at Biota Pharmaceuticals, Associate Director GBS Venture Partners, Research Manager Johnson & Johnson Research and CEO of Gene Shears Pty Ltd. Leigh also serves on the People & Culture committee and Risk committee.
    Ms Danny English Company Secretary Mar 2023
    -
    Clayton Hatch Chief Financial Officer
    -
    Danny English Company Secretary
    -
    Malte Westerhoff General Manager Europe and Global Chief Technology Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Mr A Hall 25,179,000 24.11%
    Dr S Hupert 25,137,660 24.07%
    HSBC Custody Nominees (Australia) Limited 20,907,861 20.02%
    Citicorp Nominees Pty Ltd 8,363,268 8.01%
    J P Morgan Nominees Australia Limited 8,125,600 7.78%
    BNP Paribas Noms Pty Ltd 1,335,766 1.28%
    National Nominees Limited 816,927 0.78%
    Mr Peter Terence Kempen & Mrs Elaine Margaret Kempen 629,082 0.60%
    Grain Exporters (Australia) Pty Ltd 465,000 0.45%
    Mr Michael Wu 425,242 0.41%
    Netwealth Investments Limited 370,143 0.35%
    Mr Stephen Geoffrey Wilson & Ms Denise Adele Prandi 285,037 0.27%
    Mr Colin Gregory Organ 271,000 0.26%
    Palm Beach Nominees Pty Ltd 259,654 0.25%
    Mr John Charles Plummer 250,000 0.24%
    Mr Danny Tauber 241,546 0.21%
    NewEconomy com AU Nominees Pty Limited 179,886 0.17%
    Mr Sean Michael Lambright 177,981 0.17%
    Mr Bram Vander Jagt & Mrs Maaike Vander Jagt 165,000 0.16%
    Mr Roderick Lyle 154,000 0.15%

    Profile

    since

    Note